Literature DB >> 19817723

A new rapid home test for faecal calprotectin in ulcerative colitis.

M Elkjaer1, J Burisch, V Voxen Hansen, B Deibjerg Kristensen, J-K Slott Jensen, P Munkholm.   

Abstract

BACKGROUND: Enzyme-linked immunosorbent assay (ELISA) is a time-consuming method for the measurement of faecal calprotectin. Two new quantitative rapid tests have been developed. AIM: To compare the new rapid tests with ELISA as 'Gold Standard'.
METHODS: Quantitative analysis involved the application of a sample onto the 'Lateral Flow Device'. The colour intensity of a test line was read using a laptop computer linked to a scanner (rapid test scanning). A picture taken with a mobile phone (HT photo) of the same 'Lateral Flow Device' was sent to a server via Mobile Internet and the result appeared on the phone screen after 15 s.
RESULTS: A total of 404 faecal samples were analysed. Mean differences of 1.7 mg/kg (range -23.4-20.1) ELISA vs. rapid test scanning, 6.8 mg/kg (-28-14.5) ELISA vs. HT photo and 2.9 mg/kg (-10.3-4.5) rapid test scanning vs. HT photo were found with good agreement calculated using kappa statistic (86%, 87% and 95% respectively). The Coefficients of Variation for HT photo was <10%, with a sensitivity of 96.2% and a specificity of 90.1%.
CONCLUSIONS: The new rapid tests are accurate and useful in clinical settings. Feasibility of the home test as part of disease control and self-management is currently being investigated.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19817723     DOI: 10.1111/j.1365-2036.2009.04164.x

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  10 in total

1.  Rapid Fecal Calprotectin Test and Symptom Index in Monitoring the Disease Activity in Colonic Inflammatory Bowel Disease.

Authors:  Anna-Maija Puolanne; Kaija-Leena Kolho; Henrik Alfthan; Ari Ristimäki; Harri Mustonen; Martti Färkkilä
Journal:  Dig Dis Sci       Date:  2017-09-25       Impact factor: 3.199

Review 2.  The future developments in inflammatory bowel disease care.

Authors:  Peter Irving
Journal:  Frontline Gastroenterol       Date:  2012-05-31

Review 3.  Clinicians' guide to the use of fecal calprotectin to identify and monitor disease activity in inflammatory bowel disease.

Authors:  Brian Bressler; Remo Panaccione; Richard N Fedorak; Ernest G Seidman
Journal:  Can J Gastroenterol Hepatol       Date:  2015-06-30

4.  Optimal Range of Fecal Calprotectin for Predicting Mucosal Healing in Patients with Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis.

Authors:  Bing-Jie Xiang; Min Jiang; Ming-Jun Sun; Cong Dai
Journal:  Visc Med       Date:  2021-01-21

Review 5.  Distance management of inflammatory bowel disease: systematic review and meta-analysis.

Authors:  Vivian W Huang; Krista M Reich; Richard N Fedorak
Journal:  World J Gastroenterol       Date:  2014-01-21       Impact factor: 5.742

6.  International consensus on methodological issues in standardization of fecal calprotectin measurement in inflammatory bowel diseases.

Authors:  Ferdinando D'Amico; David T Rubin; Paulo Gustavo Kotze; Fernando Magro; Britta Siegmund; Taku Kobayashi; Pablo A Olivera; Peter Bossuyt; Lieven Pouillon; Edouard Louis; Eugeni Domènech; Subrata Ghosh; Silvio Danese; Laurent Peyrin-Biroulet
Journal:  United European Gastroenterol J       Date:  2021-05-07       Impact factor: 4.623

Review 7.  Expert opinion for use of faecal calprotectin in diagnosis and monitoring of inflammatory bowel disease in daily clinical practice.

Authors:  Catherine Reenaers; Peter Bossuyt; Pieter Hindryckx; Hilde Vanpoucke; Anneline Cremer; Filip Baert
Journal:  United European Gastroenterol J       Date:  2018-06-20       Impact factor: 4.623

8.  Rapid Detection of Escherichia coli O157 and Shiga Toxins by Lateral Flow Immunoassays.

Authors:  Jinliang Wang; Robab Katani; Lingling Li; Narasimha Hegde; Elisabeth L Roberts; Vivek Kapur; Chitrita DebRoy
Journal:  Toxins (Basel)       Date:  2016-03-25       Impact factor: 4.546

Review 9.  Quality of care in inflammatory bowel diseases: What is the best way to better outcomes?

Authors:  Matthew Strohl; Lorant Gonczi; Zsuzsanna Kurt; Talat Bessissow; Peter L Lakatos
Journal:  World J Gastroenterol       Date:  2018-06-14       Impact factor: 5.742

10.  Experience of patients with inflammatory bowel disease in using a home fecal calprotectin test as an objective reported outcome for self-monitoring.

Authors:  Shu-Chen Wei; Chien-Chih Tung; Meng-Tzu Weng; Jau-Min Wong
Journal:  Intest Res       Date:  2018-10-10
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.